loader

Nuvation Bio Inc.

NYSE:NUVB
1 min read

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer.

Latest News

More News

Latest News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES